LDE225 for Patients With PTCH1 or SMO Mutated Tumors (SIGNATURE)

Novartis

Status and phase

Terminated

Phase 2

Conditions

PTCH1 or SMO Activated Solid and Hematologic Tumors

Treatments

Drug: LDE225

Study type

Interventional

Funder types

Industry

Identifiers

NCT02002689

CLDE225XUS20

Details and patient eligibility

About

The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study

Enrollment

10 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient has confirmed diagnosis of a select solid tumor (except medulloblastoma, basal cell carcinoma and pancreatic adenocarcinoma) or hematological malignancy (except CML, ALL and AML).
Patient has pre-identified tumor with a PTCH1 or SMO mutation.
Patient has received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.
Patient has progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Exclusion criteria

Patients has received prior treatment with LDE225.
Patients has neuromuscular disorders associated with elevated CK (i.e. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis
Patients has primary CNS tumor or CNS tumor involvement
Patient has received chemotherapy or anticancer therapy ≤ 4 weeks prior to starting study drug